Safety of UFRJvac, Trivalent COVID-19 Vaccine

Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes in an Elderly Population

NCT04983537 ·Status: UNKNOWN ·Phase: PHASE2

Effectiveness of the Adsorbed Vaccine COVID-19 (Coronavac) Among Education and Public Safety Workers With Risk Factors for Severity

NCT04789356 ·Status: UNKNOWN ·Phase: PHASE4

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

NCT07300839 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults

NCT01263691 ·Status: COMPLETED ·Phase: PHASE1

Local and General Immune Response After Coronavirus Disease (COVID-19) Vaccination in Volunteers

NCT04996238 ·Status: COMPLETED ·Phase: NA

A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy People

NCT05683561 ·Status: UNKNOWN ·Phase: PHASE3

A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine

NCT04683224 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3

A Study to Assess the Safety and Immunogenicity of the Coronavac Vaccine Against COVID-19

NCT04756830 ·Status: UNKNOWN ·Phase: PHASE4

Study of Immunogenicity Equivalence of a Homologous Third Dose of Covid-19 (Recombinante) Vaccine

NCT05142488 ·Status: UNKNOWN ·Phase: PHASE4

Phase II/III Randomized Clinical Trial of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine

NCT05354024 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years

NCT07069309 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Effect of Different SARS-CoV-2 Vaccine Schedules and Vaccination Intervals on Reactogenicity and Humoral Immunogenicity

NCT05076227 ·Status: COMPLETED

Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac or a Formulation of SCB-2019 (COVID-19)

NCT05087368 ·Status: UNKNOWN ·Phase: PHASE2

Immunogenicity After COVID-19 Vaccines in Adapted Schedules

NCT06189040 ·Status: COMPLETED ·Phase: PHASE4

A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older

NCT05603052 ·Status: COMPLETED ·Phase: PHASE3

A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults

NCT05037097 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

To Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy Adults

NCT04885361 ·Status: UNKNOWN ·Phase: PHASE1

Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years

NCT04895982 ·Status: COMPLETED ·Phase: PHASE2

A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination

NCT05911048 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly

NCT05283902 ·Status: COMPLETED

Safety and Immunogenicity of COVI-VAC as a Booster Dose in Adults Previously Vaccinated Against COVID-19

NCT05233826 ·Status: COMPLETED ·Phase: PHASE1

Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines

NCT05372588 ·Status: COMPLETED ·Phase: PHASE3

Study to Assess Safety, Reactogenicity and Immunogenicity of the VACCINE RNA MCTI CIMATEC HDT (HDT-301) Vaccine Against COVID-19

NCT04844268 ·Status: UNKNOWN ·Phase: PHASE1

Fourth BNT162b2 COVID-19 Vaccine Dose

NCT05231005 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine

NCT05293665 ·Status: UNKNOWN ·Phase: PHASE3